RFA-HG-24-021: Population Genomic Screening in Primary Care Cooperative Agreement (U01 - Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 2, 2024.
From the official notice on Grants.gov, last changed August 15, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsRequired
- Funded byNHGRI
- Median yearly award$927,717
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-HG-24-021 were run by National Human Genome Research Institute (NHGRI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HG-24-021 in the NIH Guide.
Key dates
| Posted | August 14, 2024 |
|---|---|
| Deadline | December 2, 2024 |
| Archived by Grants.gov | January 7, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) solicits applications for an implementation and evidence generation pilot program of population screening for common, actionable genomic conditions predominantly in the primary care setting. Specifically, the multi-site program will: 1) select, implement, and evaluate screening for 4-8 genomic conditions in diverse populations and primary care settings; 2) use established strategies for meaningful community engagement in all phases of design, conduct, and evaluation; and 3) develop effective strategies for connecting patients found to have genomic risk variants to follow-up care. This NOFO runs in parallel with companion NOFOs that invite applications for the Coordinating Center (RFA-HG-24-022) and the Sequencing Center (RFA-HG-24-023).
Funded under RFA-HG-24-021 so far
NIH funded 6 projects under RFA-HG-24-021 in fiscal 2026, at 6 institutions. The median yearly award was $927,717.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| BEACON: Building Evidence for Optimal Genomic Screening Implementation in Primary Care | Wake Forest University Health Sciences | 2026 | $664,325 |
| TestMiGenes2: Population Genomic Screening in Diverse Primary Care Settings | University of Illinois at Chicago | 2026 | $914,879 |
| PopScreen: Implementing Population Genomic Screening in Primary Care | Brigham and Women's Hospital | 2026 | $1.0 million |
| Population Genomic Screening in Primary Care | University of Alabama at Birmingham | 2026 | $831,462 |
| The Yale Population Genomic Screening Pilot: Outcomes and Best Practices for Implementation Across Different Clinical Settings. | Yale University | 2026 | $940,555 |
| Population genomic screening in primary care practices serving an urban population | University of Pennsylvania | 2026 | $963,225 |
Who has won Human Genome Research grants before
From fiscal 2021 to 2025, Human Genome Research (93.172) awarded $2.2 billion across 1,255 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 59 | $153 million |
| University of Washington | Washington | 46 | $123 million |
| The Broad Institute, Inc | Massachusetts | 22 | $119 million |
| University of California Santa Cruz | California | 17 | $64.7 million |
| Baylor College of Medicine | Texas | 24 | $62.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HG-24-021 still open?
No. It closed on December 2, 2024.
Who can apply for Population Genomic Screening in Primary Care Cooperative Agreement (U01 - Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Population Genomic Screening in Primary Care Cooperative Agreement (U01 - Clinical Trial Required)?
Closed December 2, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-HG-24-021?
NIH RePORTER lists 6 projects funded under RFA-HG-24-021 in fiscal 2026, at 6 institutions. The most were at Wake Forest University Health Sciences, University of Illinois at Chicago, Brigham and Women's Hospital.
Who has won Human Genome Research grants before?
The largest recipients over five fiscal years were The Leland Stanford Junior University, University of Washington, The Broad Institute, Inc. The program made 1,255 awards worth $2.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)